McLintock, C. Still casting its long shadow: rheumatic heart disease in Australia and New Zealand. International Medical Journal 2012; 42(9): 963–966.CrossRefGoogle ScholarPubMed

Sadler, L, McCowan, L, White, H et al. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG: An International Journal of Obstetrics and Gynecology 2000; 107(2): 245–253.CrossRefGoogle ScholarPubMed

Elkayam, U, Bitar, F. Valvular heart disease and pregnancy. Journal of the American College of Cardiology 2005; 46(3): 403–410.CrossRefGoogle ScholarPubMed

Eikelboom, JW, Connolly, SJ, Brueckmann, M et al. Dabigatran versus warfarin in patients with mechanical heart valves. New England Journal of Medicine 2013; 369(13): 1206–14.Google Scholar

European Society of Gynecology; Association for European Pediatric Cardiology; German Society for Gender Medicine; Regitz-Zagrosek, V, Blomstrom Lundqvist, C, Borghi, C et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal 2011; 32(24): 3147–3197.Google ScholarPubMed

Nishimura, RA, Otto, CM, Bonow, RO et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2014; 63(22): e57–185.CrossRefGoogle Scholar

Bates, SM, Greer, IA, Middeldorp, S et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e691S–736S.CrossRefGoogle ScholarPubMed

McLintock, C. Anticoagulant choices in pregnant women with mechanical heart valves: balancing maternal and fetal risks – the difference the dose makes. Thrombosis Research 2013; 131 (Suppl 1): S8–10.CrossRefGoogle ScholarPubMed

Schelleman, H, Limdi, NA, Kimmel, SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 2008; 9(9): 1331–1346.Google Scholar

McLintock, C, McCowan, LM, North, RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG: An International Journal of Obstetrics and Gynecology 2009; 116(12): 1585–1592.Google Scholar

Mazibuko, B, Ramnarain, H, Moodley, J. An audit of pregnant women with prosthetic heart valves at a tertiary hospital in South Africa: a five-year experience. Cardiovascular Journal of Africa 2012; 23(4): 216–221.CrossRefGoogle Scholar

Suri, V, Keepanasseril, A, Aggarwal, N et al. Mechanical valve prosthesis and anticoagulation regimens in pregnancy: a tertiary center experience. European Journal of Obstetrics & Gynecology and Reproductive Biology 2011; 159(2): 320–323.CrossRefGoogle Scholar

Becker, MH, Genieser, NB, Finegold, M, Miranda, D, Spackman, T. Chondrodysplasis punctata: is maternal warfarin therapy a factor? American Journal of Diseases of Childhood 1975; 129(3): 356–359.CrossRefGoogle ScholarPubMed

Hall, JG, Pauli, RM, Wilson, KM. Maternal and fetal sequelae of anticoagulation during pregnancy. American Journal of Medicine 1980; 68(1): 122–140.CrossRefGoogle ScholarPubMed

Howe, AM, Lipson, AH, de Silva, M, Ouvrier, R, Webster, WS. Severe cervical dysplasia and nasal cartilage calcification following prenatal warfarin exposure. American Journal of Medical Genetics 1997; 71(4): 391–396.Google Scholar

Howe, AM, Hawkins, JK, Webster, WS. The growth of the nasal septum in the 6–9 week period of foetal development – Warfarin embryopathy offers a new insight into prenatal facial development. Australian Dental Journal 2004; 49(4): 171–176.CrossRefGoogle ScholarPubMed

Franco, B, Meroni, G, Parenti, G et al. A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. Cell 1995; 81(1): 15–25.Google Scholar

van Driel, D, Wesseling, J, Sauer, PJ et al. Teratogen update: fetal effects after in utero exposure to coumarins: overview of cases, follow-up findings, and pathogenesis. Teratology 2002; 66(3): 127–140.CrossRefGoogle ScholarPubMed

McLintock, C. Thromboembolism in pregnancy: challenges and controversies in the prevention of pregnancy-associated venous thromboembolism and management of anticoagulation in women with mechanical prosthetic heart valves. Best Practice & Research Clinical Obstetrics & Gynaecology 2014; 28(4): 519–536.CrossRefGoogle ScholarPubMed

Wong, V, Cheng, CH, Chan, KC. Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. American Journal of Medical Genetics 1993; 45(1): 17–21.Google Scholar

Van Driel, D, Wesseling, J, Rosendaal, FR et al. Growth until puberty after in utero exposure to coumarins. American Journal of Medical Genetics 2000; 95(5): 438–443.3.0.CO;2-Z>CrossRefGoogle ScholarPubMed

Greer, FR. Vitamin K the basics – what’s new? Early Human Development 2010; 86 (Suppl 1): 43–47.Google Scholar

Vitale, N, De Feo, M, Cotrufo, M. Anticoagulation for prosthetic heart valves during pregnancy: the importance of warfarin daily dose. European Journal of Cardiothoracic Surgery 2002; 22(4): 656; author reply 7.CrossRefGoogle ScholarPubMed

Cotrufo, M, De Feo, M, De Santo, LS et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstetrics and Gynecology 2002; 99(1): 35–40.Google ScholarPubMed

Soma-Pillay, P, Nene, Z, Mathivha, TM, Macdonald, AP. The effect of warfarin dosage on maternal and fetal outcomes in pregnant women with prosthetic heart valves. Obstetric Medicine 2011; 4: 24–27.Google Scholar

van Hagen, IM, Roos-Hesselink, JW, Ruys, TP et al. Pregnancy in women with a mechanical heart valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease (ROPAC). Circulation 2015; 132(2): 132–142.CrossRefGoogle Scholar

Lee, JH, Park, NH, Keum, DY, Choi, SY, Kwon, KY, Cho, CH. Low molecular weight heparin treatment in pregnant women with a mechanical heart valve prosthesis. Journal of Korean Medical Science 2007; 22(2): 258–261.CrossRefGoogle ScholarPubMed

De Santo, LS, Romano, G, Della Corte, A et al. Mechanical aortic valve replacement in young women planning on pregnancy: maternal and fetal outcomes under low oral anticoagulation, a pilot observational study on a comprehensive pre-operative counseling protocol. Journal of the American College of Cardiology 2012; 59(12): 1110–1115.CrossRefGoogle ScholarPubMed

Chan, WS, Anand, S, Ginsberg, JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Archives of Internal Medicine 2000; 160(2): 191–196.Google Scholar

Arnaout, MS, Kazma, H, Khalil, A et al. Is there a safe anticoagulation protocol for pregnant women with prosthetic valves? Clinical and Experimental Obstetrics & Gynecology 1998; 25(3): 101–104.Google Scholar

Basude, S, Hein, C, Curtis, SL, Clark, A, Trinder, J. Low-molecular-weight heparin or warfarin for anticoagulation in pregnant women with mechanical heart valves: what are the risks? A retrospective observational study. BJOG: An International Journal of Obstetrics and Gynecology 2012; 119(8): 1008–1013; discussion 12–3.CrossRefGoogle ScholarPubMed

Meschengieser, SS, Fondevila, CG, Santarelli, MT, Lazzari, MA. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart 1999; 82(1): 23–26.CrossRefGoogle ScholarPubMed

Nassar, AH, Hobeika, EM, Abd Essamad, HM et al. Pregnancy outcome in women with prosthetic heart valves. American Journal of Obstetrics and Gynecology 2004; 191(3): 1009–1013.Google Scholar

Kawamata, K, Neki, R, Yamanaka, K et al. Risks and pregnancy outcome in women with prosthetic mechanical heart valve replacement. Circulation Journal 2007; 71(2): 211–213.CrossRefGoogle ScholarPubMed

McLintock, C. Anticoagulant therapy in pregnant women with mechanical prosthetic heart valves: no easy option. Thrombosis Research 2011; 127 (Suppl 3): S56–60.Google Scholar

Oran, B, Lee-Parritz, A, Ansell, J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thrombosis and Haemostasis 2004; 92(4): 747–751.Google ScholarPubMed

Abildgaard, U, Sandset, PM, Hammerstrom, J, Gjestvang, FT, Tveit, A. Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. Thrombosis Research 2009; 124(3): 262–267.Google Scholar

Chitsike, RS, Jacobson, BF, Manga, P et al. A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. Clinical and Applied Thrombosis/Hemostasis 2011; 17(4): 313–319.CrossRefGoogle Scholar

Goland, S, Schwartzenberg, S, Fan, J et al. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels? Journal of Cardiovascular Pharmacology and Therapeutics 2014; 19(5): 451–456.CrossRefGoogle ScholarPubMed

Quinn, J, Von Klemperer, K, Brooks, R et al. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience. Hematologica 2009; 94(11): 1608–1612.CrossRefGoogle ScholarPubMed

Yinon, Y, Siu, SC, Warshafsky, C et al. Use of low molecular weight heparin in pregnant women with mechanical heart valves. American Journal of Cardiology 2009; 104(9): 1259–1263.Google Scholar

Aventis Pharma. Heparin in pregnancy: cardiac valve thromboprophylaxis. Data on file; 1999.Google Scholar

Sanofi. Product monograph for Lovenox; 2015.Google Scholar

Gouin-Thibault, I, Pautas, E, Siguret, V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Safety 2005; 28(4): 333–349.CrossRefGoogle ScholarPubMed

Elkayam, U, Goland, S. The search for a safe and effective anticoagulation regimen in pregnant women with mechanical prosthetic heart valves. Journal of the American College of Cardiology 2012; 59(12): 1116–1118.CrossRefGoogle ScholarPubMed

Barbour, LA, Oja, JL, Schultz, LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. American Journal of Obstetrics and Gynecology 2004; 191(3): 1024–1029.CrossRefGoogle ScholarPubMed

Turpie, AG, Gent, M, Laupacis, A et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement New England Journal of Medicine 1993; 329(8): 524–529.CrossRefGoogle ScholarPubMed

Massonnet-Castel, S, Pelissier, E, Bara, L et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Hemostasis 1986; 16(2): 139–146.Google Scholar

Tran, HA, Chunilal, SD, Harper, PL et al. An update of consensus guidelines for warfarin reversal. Medical Journal of Australia 2013; 198(4): 198–199.CrossRefGoogle ScholarPubMed

Casais, P, Rolandi, F. Prosthetic valve thrombosis in pregnancy: a promising treatment for a rare and mostly preventable complication. Circulation 2013; 128(5): 481–482.Google Scholar

Orme, ML, Lewis, PJ, de Swiet, M et al. May mothers given warfarin breast-feed their infants? BMJ 1977; 1(6076): 1564–1565.CrossRefGoogle ScholarPubMed

Richter, C, Sitzmann, J, Lang, P et al. Excretion of low molecular weight heparin in human milk. British Journal of Clinical Pharmacology 2001; 52(6): 708–710.CrossRefGoogle ScholarPubMed

NZ Heart Foundation. New Zealand Guidelines for Rheumatic Fever: Diagnosis, management and secondary prevention of acute rheumatic fever and rheumatic heart disease; 2014 (Update). Heart Foundation of New Zealand.Google Scholar

Swan, L. Congenital heart disease in pregnancy. Best Practice & Research Clinical Obstetrics & Gynaecology 2014; 28(4): 495–506.CrossRefGoogle ScholarPubMed

UK National Institute for Health and Clinical Excellence (NICE). Prophylaxis Against Infective Endocarditis: Antimicrobial Prophylaxis Against Infective Endocarditis in Adults and Children Undergoing Interventional Procedures. London: NICE; 2008.Google Scholar